Rapid emergence of a viral resistant mutant in WHV chronically infected woodchucks treated with lamivudine and a pre-S/S CHO-derived hepatitis B virus vaccine

Vaccine

Volumn 25, Issue 26, 2007, Pages 4895-4902

  D'Ugo, Emilio ^a   Kondili, Loreta A ^a   Canitano, Andrea ^a   Catone, Stefania ^a   Giuseppetti, Roberto ^a   Gallinella, Bruno ^c   Palmieri, Giampiero ^b   Orobello, Sara ^a   Argentini, Claudio ^a   Glück, Reinhard ^d   Rapicetta, Maria ^a  

^a Viral Hepatitis Unit   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d Berna Biotech AG   (Switzerland)

Author keywords

HBV; Lamivudine; Mutant; Vaccine; WHV; Woodchuck

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HEPATITIS B; HEPATITIS B VIRUS; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS RESISTANCE; WOODCHUCK;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS, WOODCHUCK; INFLAMMATION; KINETICS; LAMIVUDINE; LIVER; MARMOTA; MONOCYTES; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VACCINATION;

EID: 34249699105     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.030     Document Type: Article

References (42)

1. WHO. The world health report 1997: conquering suffering, enriching humanity. Geneva, Switzerland, World Health Organization.
2. WHO. Hepatitis B. World Health Organization Fact Sheet No. 204 (Revised October 2000). WHO Web site. http://www.who.int/mediacentre/factsheets/fs204/en/print.html.
3. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 (1998) 1670-1677
4. Lau D.T., Khokhar M.F., Doo E., Ghany M.G., Herion D., Park Y., et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32 (2000) 828-834
5. Vandepapelierè P. Therapeutic vaccination against chronic viral infections. Lancet Infect Dis 2 (2002) 353-367
6. Cote P.J., and Gerin J.L. The woodchuck as a model of hepadnavirus infection, pathogenesis and therapy. Forum Trends Exp Clin Med 6 (1996) 131-159
7. Roggendorf M., and Tolle T.K. The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology 38 (1995) 100-112
8. Korba B.E., Cote P.J., Hornbuckle W.E., Tennant B.C., and Gerin J.L. Treatment of chronic woodchuck hepatitis virus infection in the eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 31 (2000) 1165-1175
9. Menne S., and Cote P.J. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol 13 (2007) 104-124
10. Argentini C., Giuseppetti R., D'Ugo E., La Sorsa V., Tritarelli E., Orobello S., et al. A pre-S/S CHO-derived hepatitis B virus vaccine protects woodchucks from WHV productive infection. Vaccine 23 (2005) 3649-3656
11. La Sorsa V., Argentini C., Bruni R., Villano U., Giuseppetti R., and Rapicetta M. In vivo transmission and dynamics of deleted genomes after experimental infection of woodchuck hepatitis B virus in adult animals. Virus Genes 25 (2002) 147-157
12. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis Program for Windows 95/98/NT. Nucleic Acids Res 41 (1999) 95-98
13. Stuyver L.J., Locarnini S.A., Lok A., Richman D.D., Carman W.F., Dienstag J.L., et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33 (2001) 751-757
14. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., and Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 284 (1999) 825-829
15. Menne S., Maschke J., Tolle T., Kreuzfelder E., Grosse-Wilde H., and Roggendorf M. Determination of peripheral blood mononuclear cell responses to mitogens and woodchuck hepatitis virus core antigen in woodchucks by 5-bromo-2-deoxyuridine or 2[3H] adenine. incorporation. Arch Virol 142 (1997) 511-521
16. D'Ugo E., Paroli M., Palmieri G., Giuseppetti R., Argentini C., Tritarelli E., et al. Immunization of woodchucks with adjuvanted sHDAg (p24): immune response and outcome following challenge. Vaccine 22 (2004) 457-466
17. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
18. Rajagopalan P., Boudinot F.D., Chu C.K., Tennant B.C., Baldwin B.H., and Schinazi R.F. Pharmacokinetics of (-)-2′-3′-dideoxy-3′-thiacytidine in woodchucks. Antimicrob Agents Chemother 40 (1996) 642-645
19. Richman D.D. The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res 29 (1996) 31-33
20. Locarnini S., Hatzakis A., Heathcote J., Keeffe E.B., Liang T.J., Mutimer D., et al. Management of antiviral resistance in patients with chronic hepatitis B. Antiviral Ther 9 (2004) 679-693
21. Nowak M.A., Bonhoeffer S., Hill A.M., Boehme R., Thomas H.C., and McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 93 (1996) 4398-4402
22. Mason W.S., Cullen J., Moraleda G., Saputelli J., Aldrich C.E., Miller D.S., et al. Lamivudine therapy of WHV-infected woodchucks. Virology 245 (1998) 18-32
23. Zhou T., Saputelli J., Aldrich C.E., Deslauriers M., Condreay L.D., and Mason W.S. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother 43 (1999) 1947-1954
24. Zhu Y., Yamamoto T., Cullen J., Saputelli J., Aldrich C.E., Miller D.S., et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 75 (2001) 311-322
25. Hervas-Stubbs S., Lasarte J.J., Sarobe P., Vivas I., Condreay L., Cullen J.M., et al. T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. J Hepatol 35 (2001) 105-111
26. Tatti K.M., Korba B.E., Stang H.L., Peek S., Gerin J.L., Tennant B.C., et al. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. Antiviral Res 55 (2002) 141-150
27. Jacob J.R., Korba B.E., Cote P.J., Toshkov I., Delaney W.E., Gerin IV J.L., et al. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antiviral Res 63 (2004) 115-121
28. Hurwitz S.J., Tennant B.C., Korba B.E., Gerin J.L., and Schinazi R.F. Pharmacodynamics of (-)-beta-2′,3′-dideoxy-3′-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans. Antimicrob Agents Chemother 42 (1998) 2804-2809
29. Yeh C.T., Chien R.N., Chu C.M., and Liaw Y.F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31 (2000) 1318-1326
30. Yamamoto T., Litwin S., Zhou T., Zhu Y., Condreay L., Furman P., et al. Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2′-fluoro-5-methyl-beta-l-arabinofuranosyluracil. J Virol 76 (2002) 1213-1223
31. Chayama K., Suzuki Y., Kobayashi M., Kobayashi M., Tsubota A., Hashimoto M., et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27 (1998) 1711-1716
32. Zhou T., Guo J.T., Nunes F.A., Molnar-Kimber K.L., Wilson J.M., Aldrich C.E., et al. Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections. J Virol 74 (2000) 11754-11763
33. Mancini M., Hadchouel M., Tiollais P., Pourcel C., and Michel M.L. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse" to HBsAg. J Med Virol 39 (1993) 67-74
34. Mancini M., Hadchouel M., Davis H.L., Whalen R.G., Tiollais P., and Michel M.L. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci USA 93 (1996) 12496-12501
35. Pol S., Driss F., Michel M.L., Nalpas B., Berthelot P., and Brechot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet 343 (1994) 1460-1463
36. Couillin I., Pol S., Mancini M., Driss F., Brechot C., Tiollais P., et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 180 (1999) 15-26
37. Horiike N., Fazle Akbar S.M., Michitaka K., Joukou K., Yamamoto K., Kojima N., et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 32 (2005) 156-161
38. Menne S., Roneker C.A., Korba B.E., Gerin J.L., Tennant B.C., and Cote P.J. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-l-arabinofuranosyl)-uracil (l-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 76 (2002) 5305-5314
39. Korba B.E., Cote P., Hornbuckle W., Tennant B.C., and Gerin J.L. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 31 (2000) 1165-1175
40. Boni C., Penna A., Bertoletti A., Lamonaca V., Rapti I., Missale G., et al. Transient restoration of anti-T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39 (2003) 595-605
41. Lu M., Klaes R., Menne S., Gerlich W., Stahl B., Dienes H.P., et al. Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens. J Hepatol 39 (2003) 405-413
42. Hervas-Stubbs S., Lasarte J.J., Sarobe P., Prieto J., Cullen J., Roggendorf M., et al. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J Hepatol 27 (1997) 726-737